| Literature DB >> 27570064 |
Marie Amoroso1, Peter Achenbach2, Michael Powell1, Rebecca Coles1, Monika Chlebowska1, Lorraine Carr1, Jadwiga Furmaniak1, Marlon Scholz3, Ezio Bonifacio4, Anette-G Ziegler2, Bernard Rees Smith1.
Abstract
3 Screen, a new ELISA for the combined measurement of autoantibodies to GAD65, to IA-2 and to ZnT8, has been developed and evaluated. In the assay serum samples were incubated (overnight; 2-8°C) in ELISA plate wells coated with GAD65, IA-2 and ZnT8 followed by a wash step and incubation with biotinylated GAD65, IA-2 and ZnT8 (1h; 2-8°C,). The assay was completed by addition of streptavidin-peroxidase and tetramethylbenzidine. Samples tested in the 3 Screen were also analysed in ELISAs and radiobinding assays for the three individual autoantibodies. 129/132 (98%) samples from newly diagnosed T1DM children and 1/100 non-diabetic children controls were positive in 3 Screen. There was good agreement between 3 Screen and the individual autoantibody assays. Dilution of positive samples showed good linearity characteristics. In the 2015 Islet Autoantibody Standardization Program 3 Screen achieved 94% sensitivity, 95.6% specificity and 0.948 area under curve by ROC analysis. 3 Screen provides a simple and sensitive method for combined measurement of three major diabetes associated autoantibodies in a single sample. The assay should be a useful tool for large scale population screening for individuals at risk of developing T1DM.Entities:
Keywords: Autoantibodies; Disease prediction; GAD(65); IA-2; Population screening; Type 1 diabetes mellitus; ZnT8
Mesh:
Substances:
Year: 2016 PMID: 27570064 DOI: 10.1016/j.cca.2016.08.013
Source DB: PubMed Journal: Clin Chim Acta ISSN: 0009-8981 Impact factor: 3.786